Italia markets close in 1 hour 52 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
7,96-0,24 (-2,92%)
Al 10:37AM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente8,20
Aperto8,28
Denaro7,98 x 1800
Lettera7,99 x 900
Min-Max giorno7,96 - 8,34
Intervallo di 52 settimane7,48 - 21,59
Volume206.846
Media Volume1.762.750
Capitalizzazione549,037M
Beta (5 anni mensile)1,90
Rapporto PE (ttm)N/D
EPS (ttm)-3,10
Prossima data utili02 mag 2023 - 08 mag 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A13,06
  • GlobeNewswire

    Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

    Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas’ human resources department and the Company’s people strategy in support of its mission and goals. “Our people and our culture are

  • GlobeNewswire

    Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

    Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end On track to dose first patient in EDIT-301 EDITHAL trial for TDT in Q1 2023 and provide clinical update by year-end Entered into definitive agreement to sell iNK cell franchise and out-license certain gene editing technologies to Shoreline Biosciences CAMBRIDGE, Mas

  • GlobeNewswire

    Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

    CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 22, 2023, at 8:00 a.m. ET to discuss results for the fourth quarter and full year of 2022 and to provide a corporate update. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the